Trial · NCT00690378
Trial comparisons21
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
1 to 20 of 21
Download this page as JSON| Comparison | Source |
|---|---|
| NXL104/CAZ vs Imipenem Cilastatin: Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the End of IV Therapy Visit | Trial comparisons |
| NXL104/CAZ vs Imipenem Cilastatin: Microbiological Outcome for the Urine Pathogen E. Cloacae in ME Patients at the TOC Visit | Trial comparisons |
| NXL104/CAZ vs Imipenem Cilastatin: Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the End of IV Therapy Visit | Trial comparisons |
| NXL104/CAZ vs Imipenem Cilastatin: Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the LFU Visit | Trial comparisons |
| NXL104/CAZ vs Imipenem Cilastatin: Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the LFU Visit | Trial comparisons |
| NXL104/CAZ vs Imipenem Cilastatin: Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the TOC Visit | Trial comparisons |
| NXL104/CAZ vs Imipenem Cilastatin: Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the LFU Visit | Trial comparisons |
| NXL104/CAZ vs Imipenem Cilastatin: Microbiological Outcome for the Urine Pathogen E. Cloacae in ME Patients at the End of IV Therapy Visit | Trial comparisons |
| NXL104/CAZ vs Imipenem Cilastatin: Clinical Outcome in CE Patients at the TOC Visit | Trial comparisons |
| NXL104/CAZ vs Imipenem Cilastatin: Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the LFU Visit | Trial comparisons |
| NXL104/CAZ vs Imipenem Cilastatin: Microbiological Outcome in ME Patients at the LFU Visit | Trial comparisons |
| NXL104/CAZ vs Imipenem Cilastatin: Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the End of IV Therapy Visit | Trial comparisons |
| NXL104/CAZ vs Imipenem Cilastatin: Clinical Outcome in CE Patients at the Late Follow-up (LFU) Visit | Trial comparisons |
| NXL104/CAZ vs Imipenem Cilastatin: Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the TOC Visit | Trial comparisons |
| NXL104/CAZ vs Imipenem Cilastatin: Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the TOC Visit | Trial comparisons |
| NXL104/CAZ vs Imipenem Cilastatin: Clinical Outcome in Clinically Evaluable (CE) Patients at the End of Intravenous (IV) Therapy Visit | Trial comparisons |
| NXL104/CAZ vs Imipenem Cilastatin: Microbiological Outcome in ME Patients at the End of IV Therapy Visit | Trial comparisons |
| NXL104/CAZ vs Imipenem Cilastatin: Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the TOC Visit | Trial comparisons |
| NXL104/CAZ vs Imipenem Cilastatin: Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the End of IV Therapy Visit | Trial comparisons |
| NXL104/CAZ vs Imipenem Cilastatin: Number of Participants With Microbiological Outcome at the Test of Cure (TOC) Visit | Trial comparisons |
trials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00690378/comparisons